Interview with Rubens Lima, General Manager, Ipsen Brazil
In a past interview, you said that Ipsen is different than the “Big Pharmas” who have entered Brazil by acquisition. You’ve taken a different tack since arriving as one of…
Address: Av. Luis Carlos Berrini, 1297 cj 61 – Cidade Monções São Paulo – SP – CEP: 04571-010 Brasil,Brazil
Tel: -5693
Web: http://www.ipsen.com/en/ipsen-worldwide
Ipsen is a group that operates in the global biotechnology and pharmaceutical innovation in medical specialties with more than 20 in the world market. The Ipsen Group has a worldwide staff of about 4,000 employees. Its development strategy is based on a combination of special medicines in several therapeutic areas (oncology, endocrinology, neurology and hematology) and primary care products. The company has four R & D centers (Paris, Boston, Barcelona and London) and has a group of highly qualified researchers. More than 900 people in R & D are dedicated to the discovery of innovative medicines. This strategy is also supported by an active policy of partnerships of the Ipsen Group.
In 2010, total revenue was € 1.1 billion (USD $ 1.6 billion). Ipsen invested approximately € 220 million (USD $ 315 million, or 20% of consolidated sales) on research and development (a larger percentage of the global pharmaceutical industry). Ipsen has an extensive and sophisticated R & D program, which includes about 20 lines of research, from preclinical to Phase III.
The company’s clinical trials in Brazil are conducted in partnership with major research centers like the University of São Paulo (USP), Federal University of Rio de Janeiro (UFRJ), Universidade de Brasília (UnB) and Catholic University of Porto Alegre.
Dysport ® (Botulinum toxin type A, 500U, for the treatment of dystonias, spasticity and cosmetic uses), Somatuline ® Autogel ® (lanreotide for the treatment of acromegaly and neuroendocrine tumors), Apokyn ® (apomorphine for the treatment of the syndrome. advanced Parkinson’s), Nutropin ® (growth hormone) and INCRELEX ® (IGF-1 for the treatment of growth deficits).
In a past interview, you said that Ipsen is different than the “Big Pharmas” who have entered Brazil by acquisition. You’ve taken a different tack since arriving as one of…
Prof. Dr. Luiz Calistro Balestrassi, founder and president of NEUROTEC® – Biomedical Research & Development Company from Itajubá-MG, Brazil, and his daughter Esperança Balestrassi, Neurotec´s executive director, discuss the past,…
Paulo Vitor de Andrade, founder and director of Grupo Polar, elaborates on his journey to build the Brazilian company of reference in cold chain solutions and the company’s relentless efforts…
Poul Sorensen, director of Geistlich Pharma in Brazil, details the importance of educational activities for Geistlich’s business, the affiliate’s desire to bring new segments of Geistlich’s portfolio to Brazil and…
Jun Eguti, general manager of Grünenthal Brazil, highlights the global transformation Grünenthal has undergone in the past two years, the huge potential the Brazilian affiliate has to become one of…
Alexei Kolchin, general manager of GSK Brazil, discusses adapting to Brazil, having previously held the equivalent role in Russia, the Brazilian affiliate’s contribution to GSK’s global growth, and its embrace…
Roberto Godoy, GM of Guerbet Brazil and marketing director of Guerbet Latin America, a leading French-based contrast media company present in Brazil for the past 40 years, explains his role…
Paulo Henrique Fraccaro, superintendent of the Brazilian Medical and Dental Devices Manufacturers Association (ABIMO), describes the central role of the association within the Brazilian medtech industry, the phenomenal potential of…
Fernando Silveira F°, country manager in Brazil of ISDIN, documents the successful market entry and rapid development of this dermatology focused company in Brazil, while ISDIN has managed to establish…
Luis Fernando Lenski, head of South Cone and general manager of Galderma Brazil, provides insights into the affiliate’s heightened and tireless efforts in terms of medical education and his focus…
Juan Pablo Udry, general manager Brazil and Latin America at Boiron, the world’s undisputed leader in homeopathic medicines, provides an insightful overview of the Brazilian and Latin American landscape for…
Cesar Rengifo, senior vice president and area director Emerging Markets West at GSK, the fastest growing multinational company in both Brazil and Latin America, discusses the perfect match between GSK’s…
Ivo Mafra, president and founder of DC Logistics Brazil, a Brazilian based third party logistics (3PL) company awarded Best partner Worldwide and Latin America 2016 – WCA world, details the…
See our Cookie Privacy Policy Here
